6-phenoxymethyl-pteridine-2,4-diamine | 57963-57-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 英文名称: 6-phenoxymethyl-pteridine-2,4-diamine
• 英文别名: 6-[(Phenoxy)methyl]-2,4-pteridinediamine；2,4-Pteridinediamine, 6-(phenoxymethyl)-；6-(phenoxymethyl)pteridine-2,4-diamine
• CAS: 57963-57-2
• 化学式: C₁₃H₁₂N₆O
• 分子量: 268.278
• InChiKey: AAVNOHSYACQWOK-UHFFFAOYSA-N

物化性质

• 熔点：
  287-288 °C
• 沸点：
  557.0±60.0 °C(Predicted)
• 密度：
  1.444±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  113
• 氢给体数：
  2
• 氢受体数：
  7

安全信息

• 海关编码：
  2933990090

反应信息

• 作为产物：
  描述：

  6-溴乙基-喋啶-2,4-二胺 、 苯酚 在 NaH 作用下， 以70%的产率得到6-phenoxymethyl-pteridine-2,4-diamine
  参考文献：
  名称：

  6-(Bromomethyl)-2,4-diaminopteridine hydrobromide

  摘要：

  一种具有化学式6-(溴甲基)-2,4-二氨基喹啉盐酸盐的喹啉化合物。2,4-二氨基-6-喹啉甲醇盐酸盐与三苯基膦二溴化物或三溴化磷反应，形成6-(溴甲基)-2,4-二氨基喹啉盐酸盐。然后，分子中的溴原子可以被甲氨基苯甲酰-L-谷氨酸（甲氨基四氢叶酸）或氨基对氨基苯甲酰-L-谷氨酸（氨基四氢叶酸）等功能基团所取代。

  公开号：

  US04077957A1

文献信息

• 6-(Bromomethyl)-2,4-diaminopteridine hydrobromide
  申请人：The United States of America as represented by the Department of Health,

  公开号：US04077957A1

  公开（公告）日：1978-03-07

  A pteridine compound having the formula of 6-(bromomethyl)-2,4-diaminopteridine hydrobromide. 2,4-diamino-6-pteridine-methanol.HBr is reacted with triphenylphosphine dibromide or phosphorus tribromide to form 6-(bromomethyl)-2,4-diaminopteridine hydrobromide. The bromine atom in the molecule can then be replaced with the functional group, N-[4-(methylamino)-benzoyl]-L-glutamic acid in the case of methotrexate and N-(4-aminobenzoyl)-L-glutamic acid in the case of aminopterin.

  一种具有化学式6-(溴甲基)-2,4-二氨基喹啉盐酸盐的喹啉化合物。2,4-二氨基-6-喹啉甲醇盐酸盐与三苯基膦二溴化物或三溴化磷反应，形成6-(溴甲基)-2,4-二氨基喹啉盐酸盐。然后，分子中的溴原子可以被甲氨基苯甲酰-L-谷氨酸（甲氨基四氢叶酸）或氨基对氨基苯甲酰-L-谷氨酸（氨基四氢叶酸）等功能基团所取代。
• Inhibition of Neuronal Nitric Oxide Synthase by 4-Amino Pteridine Derivatives:  Structure−Activity Relationship of Antagonists of (6<i>R</i>)-5,6,7,8-Tetrahydrobiopterin Cofactor
  作者：Lothar G. Fröhlich、Peter Kotsonis、Hermann Traub、Shahriyar Taghavi-Moghadam、Najim Al-Masoudi、Heinrich Hofmann、Hartmut Strobel、Hans Matter、Wolfgang Pfleiderer、Harald H. H. W. Schmidt

  DOI：10.1021/jm981129a

  日期：1999.10.1

  The family of nitric oxide synthases (NOS) catalyzes the conversion of L-arginine to L-citrulline and nitric oxide (NO), an important cellular messenger molecule which has been implicated in the pathophysiology of septic shock and inflammatory and neurodegenerative disease states. NOS can be maximally activated by the ubiquitous cofactor, (6R)-5,6,7,8-tetrahydrobiopterin (H(4)Bip), and antagonists of H(4)Bip may be of therapeutic importance to inhibit pathologically high NO formation. The 4-amino substituted analogue of H(4)Bip was reported to be a potent NOS inhibit-or. Therefore, we developed a series of novel 4-amino pteridine derivatives, antipterins, to pharmacologically target the neuronal isoform of nitric oxide synthase (NOS-I). To functionally characterize the pterin/anti-pterin interaction and establish a structure-activity relationship (SAR), we systematically altered the substituents in the 2-, 4-, 5-, 6-, and 7-position of the pteridine nucleus. Varying the substitution pattern in the 2-, 5-, and 7-position resulted in no significant inhibitory effect on enzyme activity. In contrast, bulky substituents in the B-position, such as phenyl, markedly increased the inhibitory potency of the reduced 4-amino-5,6,7,8-tetrahydropteridines, possibly as a consequence of hydrophobic interactions within NOS-I. However, this was not the case for the aromatic 4-amino pteridines. Interestingly, chemical modification of the 4-amino substituent by dialkyl/diaralkylation together with 6-arylation of the aromatic 2,4-diamino pteridine resulted in potent and efficacious inhibitors of NOS-I, suggesting possible hydrophilic and hydrophobic interactions within NOS-I. This SAR agrees with (a) the recently published crystal structure of the oxygenase domain of the inducible NOS isoform (NOS-II) and (b) the comparative molecular field analysis of selected NOS-I inhibitors, which resulted in a 3D-QSAR model of the pterin binding site interactions. Further optimization should be possible when the full length structure of NOS-I becomes available.
• US4077957A
  申请人：——

  公开号：US4077957A

  公开（公告）日：1978-03-07
• US4079056A
  申请人：——

  公开号：US4079056A

  公开（公告）日：1978-03-14
• MONTGOMERY J. A.; PIPER J. R.; ELLIOTT R. D.; ROBERTS E. C.; TEMPLE C.; S+, J. HETEROCYCL. CHEM., 1979, 16, NO 3, 537-539
  作者：MONTGOMERY J. A.、 PIPER J. R.、 ELLIOTT R. D.、 ROBERTS E. C.、 TEMPLE C.、 S+

  DOI：——

  日期：——